Deep LS GmbH offers computational solutions to accelerate drug discovery and development for pharmaceutical and biopharmaceutical companies. Their platform utilizes machine learning to identify potential drug molecules, optimize their properties like solubility and ADME, and pinpoint binding sites on targets.
Funding
Funding not disclosed
Founders
Product
Problem
The pharmaceutical and biopharmaceutical industries face challenges in efficiently identifying and optimizing novel drug candidates. Traditional methods for drug discovery and development can be time-consuming and resource-intensive, requiring extensive experimental validation.
Solution
Deep LS GmbH provides computational solutions for drug discovery and development, leveraging data science and machine learning expertise. The company applies advanced techniques to accelerate the identification of potential drug molecules and assess their properties. By transferring successful approaches from other industries, Deep LS GmbH aims to enhance the efficiency of the drug development lifecycle. Their focus is on delivering fact-based insights that complement existing client expertise.
Target Audience
The primary customers are companies within the pharmaceutical and biopharmaceutical sectors engaged in drug discovery and development.
Features
- **Generative Ligand Finder:** Designs small molecules, peptides, or proteins optimized to bind with a specified target molecule from vast chemical spaces.
- **Feature Assessment:** Analyzes and optimizes compounds for solubility, toxicity, ADME (Absorption, Distribution, Metabolism, Excretion) properties, and other critical criteria.
- **Binding Site Identification:** Identifies the specific binding sites on protein or RNA targets of interest.
- **Machine Learning Integration:** Utilizes state-of-the-art machine learning models and contributes to scientific advancements in the field.